Alessandra Ferrajoli

Statistics

Publications

348

Citations

26.2K

H-Index

Active since

1992

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

University of California, Irvine

Alessandra Ferrajoli is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and hematologic malignancy therapy.

ORCID

Publications per year

1992–2025

348

Publications

348

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

Hagop M. Kantarjian, Yasuhiro Oki, Guillermo Garcia‐Manero et al. · Blood · 2006 · 689 citations · Full text

Medicine, Oncology, Pharmacology +16

Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia

William G. Wierda, Susan O’Brien, Sijin Wen et al. · Journal of Clinical Oncology · 2005 · 523 citations

Medicine, Oncology, Pharmacotherapy +12

Ibrutinib and Venetoclax for First-Line Treatment of CLL

Nitin Jain, Michael J. Keating, Philip A. Thompson et al. · New England Journal of Medicine · 2019 · 504 citations · Full text

Medicine, Hematology, Oncology +17

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

Guillermo Garcia‐Manero, Hui Yang, Carlos E. Bueso‐Ramos et al. · Blood · 2007 · 461 citations

Medicine, Hematology, Oncology +16

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Jennifer R. Brown, Barbara Eichhorst, Peter Hillmen et al. · New England Journal of Medicine · 2022 · 457 citations · Full text

Medicine, Oncology, Pharmacology +16

1–5 of 348